IBDEI0KM ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9765,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9765,1,3,0)
 ;;=3^Eyelid/Canthus,SCC
 ;;^UTILITY(U,$J,358.3,9765,1,4,0)
 ;;=4^173.12
 ;;^UTILITY(U,$J,358.3,9765,2)
 ;;=^340468
 ;;^UTILITY(U,$J,358.3,9766,0)
 ;;=173.19^^44^557^55
 ;;^UTILITY(U,$J,358.3,9766,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9766,1,3,0)
 ;;=3^Eyelid/Canthus,Malig Neopl,Oth
 ;;^UTILITY(U,$J,358.3,9766,1,4,0)
 ;;=4^173.19
 ;;^UTILITY(U,$J,358.3,9766,2)
 ;;=^340469
 ;;^UTILITY(U,$J,358.3,9767,0)
 ;;=053.20^^44^557^51
 ;;^UTILITY(U,$J,358.3,9767,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9767,1,3,0)
 ;;=3^Eyelid,Herpes Zoster
 ;;^UTILITY(U,$J,358.3,9767,1,4,0)
 ;;=4^053.20
 ;;^UTILITY(U,$J,358.3,9767,2)
 ;;=^56937
 ;;^UTILITY(U,$J,358.3,9768,0)
 ;;=054.41^^44^557^50
 ;;^UTILITY(U,$J,358.3,9768,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9768,1,3,0)
 ;;=3^Eyelid,Herpes Simplex
 ;;^UTILITY(U,$J,358.3,9768,1,4,0)
 ;;=4^054.41
 ;;^UTILITY(U,$J,358.3,9768,2)
 ;;=^266563
 ;;^UTILITY(U,$J,358.3,9769,0)
 ;;=078.0^^44^557^77
 ;;^UTILITY(U,$J,358.3,9769,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9769,1,3,0)
 ;;=3^Molluscum Contagiosum
 ;;^UTILITY(U,$J,358.3,9769,1,4,0)
 ;;=4^078.0
 ;;^UTILITY(U,$J,358.3,9769,2)
 ;;=^78675
 ;;^UTILITY(U,$J,358.3,9770,0)
 ;;=228.1^^44^557^76
 ;;^UTILITY(U,$J,358.3,9770,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9770,1,3,0)
 ;;=3^Lymphangioma
 ;;^UTILITY(U,$J,358.3,9770,1,4,0)
 ;;=4^228.1
 ;;^UTILITY(U,$J,358.3,9770,2)
 ;;=^72391
 ;;^UTILITY(U,$J,358.3,9771,0)
 ;;=238.2^^44^557^3
 ;;^UTILITY(U,$J,358.3,9771,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9771,1,3,0)
 ;;=3^Benign Neopl,Oth & Unspec Sites/Tissue
 ;;^UTILITY(U,$J,358.3,9771,1,4,0)
 ;;=4^238.2
 ;;^UTILITY(U,$J,358.3,9771,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,9772,0)
 ;;=242.00^^44^557^61
 ;;^UTILITY(U,$J,358.3,9772,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9772,1,3,0)
 ;;=3^Goiter Toxic Dif/Graves Thyrotoxic Exoph
 ;;^UTILITY(U,$J,358.3,9772,1,4,0)
 ;;=4^242.00
 ;;^UTILITY(U,$J,358.3,9772,2)
 ;;=^267793
 ;;^UTILITY(U,$J,358.3,9773,0)
 ;;=272.2^^44^557^101
 ;;^UTILITY(U,$J,358.3,9773,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9773,1,3,0)
 ;;=3^Xanthelasma
 ;;^UTILITY(U,$J,358.3,9773,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,9773,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,9774,0)
 ;;=360.40^^44^557^60
 ;;^UTILITY(U,$J,358.3,9774,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9774,1,3,0)
 ;;=3^Globe/Eye Degenerative,Unspec
 ;;^UTILITY(U,$J,358.3,9774,1,4,0)
 ;;=4^360.40
 ;;^UTILITY(U,$J,358.3,9774,2)
 ;;=^268563
 ;;^UTILITY(U,$J,358.3,9775,0)
 ;;=360.42^^44^557^65
 ;;^UTILITY(U,$J,358.3,9775,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9775,1,3,0)
 ;;=3^Hypertensive Blind/Absolute Glaucoma
 ;;^UTILITY(U,$J,358.3,9775,1,4,0)
 ;;=4^360.42
 ;;^UTILITY(U,$J,358.3,9775,2)
 ;;=^268565
 ;;^UTILITY(U,$J,358.3,9776,0)
 ;;=360.89^^44^557^59
 ;;^UTILITY(U,$J,358.3,9776,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9776,1,3,0)
 ;;=3^Globe D/O,Other
 ;;^UTILITY(U,$J,358.3,9776,1,4,0)
 ;;=4^360.89
 ;;^UTILITY(U,$J,358.3,9776,2)
 ;;=^268581
 ;;^UTILITY(U,$J,358.3,9777,0)
 ;;=373.01^^44^557^5
 ;;^UTILITY(U,$J,358.3,9777,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9777,1,3,0)
 ;;=3^Blepharitis,Ulcerative
 ;;^UTILITY(U,$J,358.3,9777,1,4,0)
 ;;=4^373.01
 ;;^UTILITY(U,$J,358.3,9777,2)
 ;;=^269053
 ;;^UTILITY(U,$J,358.3,9778,0)
 ;;=373.31^^44^557^49
 ;;^UTILITY(U,$J,358.3,9778,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9778,1,3,0)
 ;;=3^Eyelid,Dermatitis,Eczematous
 ;;^UTILITY(U,$J,358.3,9778,1,4,0)
 ;;=4^373.31
 ;;^UTILITY(U,$J,358.3,9778,2)
 ;;=^269060
 ;;
 ;;$END ROU IBDEI0KM
